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Occurrence of breast cancer subtypes in
adolescent and young adult women
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Abstract
Introduction: Breast cancers are increasingly recognized as heterogeneous based on expression of receptors for
estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative tumors
(ER-/PR-/HER2-) have been reported to be more common among younger women, but occurrence of the spectrum
of breast cancer subtypes in adolescent and young adult (AYA) women aged between 15 and 39 years is
otherwise poorly understood.
Methods: Data regarding all 5,605 AYA breast cancers diagnosed in California during the period 2005 to 2009,
including ER and PR status (referred to jointly as hormone receptor (HR) status) and HER2 status, was obtained
from the population-based California Cancer Registry. Incidence rates were calculated by subtype (triple-negative;
HR+/HER2-; HR+/HER2+; HR-/HER2+), and logistic regression was used to evaluate differences in subtype
characteristics by age group.
Results: AYAs had higher proportions of HR+/HER2+, triple-negative and HR-/HER2+ breast cancer subtypes and
higher proportions of patients of non-White race/ethnicity than did older women. AYAs also were more likely to
be diagnosed with stage III/IV disease and high-grade tumors than were older women. Rates of HR+/HER2- and
triple-negative subtypes in AYAs varied substantially by race/ethnicity.
Conclusions: The distribution of breast cancer subtypes among AYAs varies from that observed in older women,
and varies further by race/ethnicity. Observed subtype distributions may explain the poorer breast cancer survival
previously observed among AYAs.
Introduction
Breast cancer is the most frequently diagnosed cancer
among adolescent and young adult (AYA) women 15 to
39 years of age [1]. Currently, AYA breast cancer accounts
for approximately 14% of all AYA cancer diagnoses and
7% of all breast cancer diagnoses [1,2]. Evidence suggests
that AYA breast cancer may be etiologically as well as
clinically distinct from breast cancer in older women [2].
When breast cancer occurs in AYAs, it differs from that
occurring in older women in several ways: a worse prog-
nosis and more-aggressive phenotype, higher proportions
of high-grade and later stage tumors, lower estrogen
receptor (ER) positivity, and overexpression of human epi-
dermal growth factor receptor 2 (HER2) [1,3,4]. Under-
standing differences between AYA cancers and those
occurring in older populations has been set forth by the
National Cancer Institute and LIVESTRONG Young
Adult Alliance as important in light of stalled progress in
improving outcomes among AYAs with cancer [5].
We recently reported in a large, population-based series
from California that the hormone receptor negative, HER2
positive (HR-/HER2+) and triple-negative (ER negative/pro-
gesterone receptor (PR) negative/HER2 negative) tumors
were more common in younger women [4,6]. Other Cali-
fornia-based analyses have found a higher incidence rate of
triple-negative breast cancer in young (younger than 44
years) Blacks compared with Whites or Hispanics (2004 to
2006) [7] and that young age was associated with triple-
negative breast cancer in 1999 to 2003 [8] and 1999 to
2004 [9] data. The Carolina Breast Cancer Study also
found triple-negative breast cancer to be more common in
premenopausal than postmenopausal women [10]. How-
ever, besides triple-negative breast cancer [7], no previous
studies have reported incidence rates by molecular breast
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cancer subtypes in AYAs. Therefore, the better to under-
stand the occurrence of AYA breast cancer subtypes, we
took advantage of HER2 data recently available for breast
cancers occurring in the large and diverse California popu-
lation from 2005 to 2009. In addition, we compared the
subtype distribution and demographic and tumor charac-
teristics in AYAs with those in older premenopausal (40 to
49 years) and postmenopausal (50+ years) women.
Methods
Cancer cases
We obtained from the California Cancer Registry (CCR)
information about all female California residents diagnosed
with an invasive breast cancer (International Classification
of Disease for Oncology, 3rd Edition, (ICD-O-3) site codes
C50.0-50.9) during the period January 1, 2005, through
December 31, 2009. Individual informed consent was not
obtained, as the analysis was based on state-mandated can-
cer registry data. For each breast cancer case, we obtained
information routinely abstracted from the medical record
on age at diagnosis, race/ethnicity (Hispanic, non-Hispanic
White, non-Hispanic Black, and non-Hispanic Asian/Paci-
fic Islander, hereafter referred to as “White”, “Black”, “His-
panic”, and “Asian”), AJCC stage at diagnosis (I, II, III, IV,
or unstaged/not applicable (NA)), tumor size (≤2 cm, > 2
cm, microinvasion, diffuse, or unknown), grade (low, high,
or unknown), ER, PR, and HER2 tumor-expression status,
sequence number (first primary or non-first primary), and
prior cancer (no, yes, or unknown). The CCR has collected
information on ER and PR since 1990 and on HER2 since
1999 [8]. Before the year 2005, 41% of cases lacked HER2
data, but data completeness has increased to at least 83%
since that time. Because of the initial reduced reliability of
HER2-receptor status [11] and data completeness, we lim-
ited our analyses to between 2005 and 2009. ER and PR
were evaluated with dextran-coated charcoal assays or
immunohistochemistry (IHC); HER2 was tested with IHC
or fluorescence in situ hybridization. Each marker was
reported as positive, negative, borderline, not tested, not
recorded, or unknown, based on the test performed by the
laboratory at the reporting facility [12].
Of the 141,002 female breast cancer cases 15 years or
older diagnosed between 2005 and 2009 in California, we
excluded cases with in situ breast cancer (n = 27,276),
inflammatory carcinoma (n = 697), Paget disease (n = 26),
mammographic or xerographic diagnosis only (n = 383),
and death certificate only (n = 363). The resulting study
population (N = 112,256) included 5,605 women aged 15
to 39 years, 19,776 women aged 40 to 49 years, and 86,875
women older than 50 years at diagnosis.
Categorization of breast cancer subtypes
Breast cancer subtypes were categorized according to
tumor expression of ER, PR, and HER2. HR+/HER2- was
defined as ER or PR positive and HER2 negative; HR
+/HER2+ as ER or PR positive and HER2 positive; HR-/
HER2+ as ER and PR negative and HER2 positive; and
triple-negative as ER, PR, and HER2 negative [11,13,14].
Population denominator data
We obtained population counts by sex, race/ethnicity, and
5-year age group for the state of California from the 2000
Census Summary File 3 (SF-3) [15]. Data from the 20%
Integrated Public-Use Microdata Sample of the Census
also were used to estimate age-specific population counts
for Hispanics [16] by smoothing with a spline-based
function.
Statistical analysis
SEER*Stat software [17] was used to compute age-adjusted
incidence rates (standardized to the 2000 US standard mil-
lion population) and 95% confidence intervals (CIs) for
invasive breast cancer. We calculated incidence-rate ratios
(IRRs) comparing rates by race/ethnicity, with Whites as
the reference. To evaluate differences in the clinical char-
acteristics of breast cancer subtypes by age group (15 to
39 years versus 40 to 49 years; 15 to 39 years versus older
than 50 years), and we used logistic regression to calculate
odds ratios (OR) and associated 95% confidence intervals
(CIs). Models included race/ethnicity, year of diagnosis,
stage at diagnosis, grade, and first primary cancer, and
were analyzed by using SAS version 9.2 (Cary, NC, USA).
This project was approved by the institutional review
board of the Cancer Prevention Institute of California.
Results
The overall, age-adjusted incidence rate for breast can-
cer among all AYAs was 18.9 per 100,000 women (95%
CI, 18.4 to 19.4). Incidence of breast cancer for all sub-
types increased rapidly between 15 and 39 years of age
(Figure 1). Table 1 shows characteristics of AYA breast
tumors diagnosed. 62.8% of AYAs were diagnosed
between 35 to 39 years of age (Table 1). HR+/HER2-
was the most commonly diagnosed AYA subtype
(41.1%), followed by triple-negative (19.1%), HR+/HER2+
(15.0%) and HR-/HER2+ (8.7%). Most AYA breast can-
cer patients were of White (42.7%) or Hispanic (32.1%)
race/ethnicity. The highest proportion of stage III/IV
disease occurred for the HR-/HER2+ subtype. A higher
proportion of AYAs with triple-negative and HR-/HER2+
subtypes presented with high-grade disease than did
those diagnosed with the HR+/HER2- subtype. Nearly 7%
of AYA breast cancer patients had a prior cancer (any
type) before this breast cancer.
Substantial racial/ethnic differences were found in
AYA breast cancer. Compared with Whites, Blacks were
24% less likely to have the HR+/HER2- subtype and 61%
more likely to have the triple-negative subtype. Unlike
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in the other racial/ethnic groups, in which the incidence
of HR+/HER2- is higher than triple-negative breast can-
cer, Blacks had a similar incidence of HR+/HER2- and
triple-negative subtypes. In addition, Hispanics were
35% less likely to be diagnosed with the HR+/HER2-
subtype, and Asians were 36% less likely to be diagnosed
with the triple-negative subtype than were Whites
(Table 2).
Comparison of subtypes between age groups
HR+/HER2- was the most common subtype among all age
groups, and HR-/HER2+ was the least; however, the rela-
tive contribution of each subtype varied within age cate-
gories (Figure 2). HR+/HER2- comprised an increasing
proportion of all breast cancer diagnoses across the life
span. By contrast, the relative contribution of HR+/HER2+,
HR-/HER2+, and triple-negative decreased in successive
age groups.
Comparison of patient and clinical characteristics
between age groups
Table 3 presents findings from logistic regression models
comparing AYAs with women 40 to 49 years old and
women older than 50 years separately to understand how
characteristics differed among age groups. Compared with
women older than 50 years and relative to Whites, Hispa-
nics, Blacks, and Asians, AYAs were significantly more
likely to be diagnosed with breast cancer and all breast can-
cer subtypes. Compared with women 40 to 49 years old,
Hispanics (versus Whites) were more likely to be diagnosed
with all subtypes, and Asians (versus Whites) were more
likely to be diagnosed with HR+/HER2- and HR+/HER2+
subtypes. Black AYAs (versus Whites) were not significantly
more likely than women 40 to 49 years old to be diagnosed
with any subtype. AYAs also were significantly more likely
to be diagnosed with stage III/IV disease and high-grade
disease, except for HR-/HER2+ breast cancer, than were
older women. Compared with older women, AYAs were
less likely to have had a prior cancer.
Discussion
Our population-based study is the first to detail subtype-
specific breast cancer occurrence among AYAs, aged 15 to
39 years. Similar to older women, AYAs were most likely
to be diagnosed with the HR+/HER2- subtype of breast
cancer, followed by the triple-negative, HR+/HER2+ and
HR-/HER2+ subtypes. However, compared with older
women, AYAs had higher proportions of HR+/HER2+, tri-
ple-negative, and HR-/HER2+ breast cancer subtypes and
higher proportions of patients of non-White race/ethni-
city. We also found that subtype distributions differed by
race/ethnicity in AYAs, with Blacks and Hispanics less
likely to be diagnosed with the HR+/HER2- subtype, and
Asians less likely and Blacks more likely to be diagnosed
with the triple-negative subtype, as compared with Whites.
We also found that AYAs were more likely to be diag-
nosed with stage III/IV disease and high-grade tumors
than were older women.
Although previous studies in the CCR have found higher
proportions of triple-negative [4,6,8] and HR-/HER2+ [4,6]
subtypes in younger women, ours is the first study to
report a higher incidence of the HR+/HER2+ subtype in
AYAs compared with older age groups. This distinction is
important because HR+/HER2+, like the triple-negative
and HR-/HER2+ subtypes, may be associated with worse
survival than the HR+/HER2- subtype [10,18]. The lower
proportion of HR+/HER2- breast cancer in AYAs com-
pared with older women in our study may contribute to
the poor prognosis reported for AYA breast cancer
patients as a whole [3].
Poor prognoses among AYAs are particularly relevant to
Black, Hispanic, and Asian women, who comprised a lar-
ger proportion of young compared with older breast can-
cer patients. Our results are consistent with previous
reports of a higher incidence of breast cancer, especially
triple-negative breast cancer [7,8], in young Blacks and
relatively lower rates with increasing age for Hispanic and
Asian women compared with Whites [19,20]. Black
women have a high burden of triple-negative breast can-
cer, which is associated with poorer outcomes after breast-
conserving therapy compared with other subtypes [21]. In
contrast, Asian 15 to 39 year-olds had a much lower inci-
dence of triple-negative breast cancer, consistent with our
previous analyses [4,6]. We did not find an excess of breast
cancer among Asians, in contrast to another California
study using different methods of rate calculation [22].
Black and Hispanic women younger than 35 years have
Figure 1 Age-specific incidence rates of breast cancer by
subtypes among California women aged 15 to 39 years, 2005-
2009. Hormone receptor (HR)-positive and human epidermal
growth factor receptor 2 (HER2)-negative (diamond), HR+/HER2+
(square), HR-/HER2+ (triangle), and triple-negative (X).
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been found to have a poorer survival than White women
[23], a finding that could be due, in part, to the lower pro-
portion of HR+/HER2- cancer in Black and Hispanic
AYAs and a higher proportion of triple-negative breast
cancer in Blacks.
Risk factors for breast cancer when treated as a single
entity have been reported to differ by age [24], race/eth-
nicity [25,26], and hormone-receptor status [27-31].
Multiparity [24], prior mantle radiation for Hodgkin
lymphoma [32], oral contraceptive use [33], and a low
Table 1 Demographic and clinical characteristics of adolescents and young adults with breast cancer by subtype,a
2005 to 2009
Total HR+/HER2-a HR+/HER2+a HR-/HER2+a Triple-negativea Unclassified
(N = 5,605) (n = 2,306) (n = 843) (n = 485) (n = 1,073) (n = 898)
Characteristics N n Col% n Col% n Col% n Col% n Col%
Age group (years)
15-24 97 36 (1.6) 11 (1.3) 12 (2.5) 11 (1.0) 27 (3.0)
25-29 482 161 (7.0) 81 (9.6) 53 (10.9) 98 (9.1) 89 (9.9)
30-34 1,507 557 (24.2) 246 (29.2) 144 (29.7) 319 (29.7) 241 (26.8)
35-39 3,519 1,552 (67.3) 505 (59.9) 276 (56.9) 645 (60.1) 541 (60.2)
Race/ethnicity
White 2,394 1,050 (45.5) 347 (41.2) 198 (40.8) 430 (40.1) 369 (41.1)
Black 421 135 (5.9) 66 (7.8) 39 (8.0) 117 (10.9) 64 (7.1)
Hispanic 1,801 678 (29.4) 271 (32.2) 166 (34.2) 394 (36.7) 292 (32.5)
Asian 917 423 (18.3) 152 (18.0) 79 (16.3) 116 (10.8) 147 (16.4)
Unknown/other 72 20 (0.9) 7 (0.8) b 16 (1.5) 26 (2.9)
Year of diagnosis
2005 1,134 367 (15.9) 157 (18.6) 101 (20.8) 226 (21.1) 283 (31.5)
2006 1,133 444 (19.3) 192 (22.8) 106 (21.9) 212 (19.8) 179 (19.9)
2007 1,074 463 (20.1) 145 (17.2) 100 (20.6) 207 (19.3) 159 (17.7)
2008 1,205 540 (23.4) 168 (19.9) 103 (21.2) 239 (22.3) 155 (17.3)
2009 1,059 492 (21.3) 181 (21.5) 75 (15.5) 189 (17.6) 122 (13.6)
AJCC stage at diagnosis
I 1,435 722 (31.3) 183 (21.7) 94 (19.4) 212 (19.8) 224 (24.9)
II 2,425 956 (41.5) 365 (43.3) 199 (41.0) 541 (50.4) 364 (40.5)
III 1,102 430 (18.6) 214 (25.4) 126 (26.0) 213 (19.9) 119 (13.3)
IV 327 127 (5.5) 47 (5.6) 45 (9.3) 63 (5.9) 45 (5.0)
Unstaged/NA 316 71 (3.1) 34 (4.0) 21 (4.3) 44 (4.1) 146 (16.3)
Grade
Low 2,222 1,370 (59.4) 341 (40.5) 104 (21.4) 100 (9.3) 307 (34.2)
High 3,022 849 (36.8) 466 (55.3) 356 (73.4) 939 (87.5) 412 (45.9)
Unknown 361 87 (3.8) 36 (4.3) 25 (5.2) 34 (3.2) 179 (19.9)
Tumor size
≤2 cm 2,165 1,056 (45.8) 326 (38.9) 157 (32.4) 320 (29.8) 306 (34.0)
> 2 cm 3,093 1,177 (51.0) 479 (57.1) 284 (58.6) 705 (65.7) 448 (49.8)
Microinvasion 56 15 (0.7) 7 (0.8) 8 (1.7) b 26 (2.9)
Diffuse 38 10 (0.4) b 12 (2.5) 9 (0.8) b
Unknown 253 48 (2.1) 27 (3.2) 24 (5.0) 39 (3.6) 115 (12.8)
Lymph node involvement
No 2,761 1,155 (50.1) 358 (42.5) 189 (39.0) 566 (52.8) 493 (54.9)
Yes 2,707 1,123 (48.7) 472 (56.0) 286 (59.0) 491 (45.8) 335 (37.3)
Unknown 137 28 (1.2) 13 (1.5) 10 (2.1) 16 (1.5) 70 (7.8)
Prior cancer
First primary 5,226 2,169 (94.1) 796 (94.4) 459 (94.6) 993 (92.5) 832 (92.7)
Non-first primary 379 137 (5.9) 47 (5.6) 26 (5.4) 80 (7.5) 66 (7.3)
aHuman epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-).
bStatistic not displayed because of five or fewer cases.
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body mass index [34] are associated with breast cancer
in young women and may vary by race/ethnicity [35,36].
Although studies have found that White women are
more likely to experience risk factors for postmenopau-
sal breast cancer, similar associations based on race/eth-
nicity are less clear for young women and should be the
focus of future research. Given the differences observed
in subtype distribution by age, it is probable that sub-
type-specific risk factors explain the heterogeneity of
risk observed for breast cancer as a single entity.
Risk factor heterogeneity also has been reported by
tumor ER and PR status [29,37] and, more recently, for
HER2 status [11,29]. In pooled analyses, reproductive risk
factors (age at menarche, parity, and age at first birth) and
body mass index were associated with risk of HR positive,
but not triple-negative tumors [31]. The only risk factor
associated with the development of triple-negative tumors
was family history, which was associated positively with all
subtypes [31]. The Women’s Health Initiative also
reported appreciable differences among postmenopausal













15-24 0.7 (0.6-0.9) 0.3 (0.2-0.4) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 0.1 (0.0-0.2)
25-29 7.4 (6.8-8.1) 2.5 (2.1-2.9) 1.2 (1.0-1.5) 0.8 (0.6-1.1) 1.5 (1.2-1.8)
30-34 24.4 (23.2-25.7) 9.0 (8.3-9.8) 4.0 (3.5-4.5) 2.3 (2.0-2.7) 5.2 (4.6-5.8)
35-39 54.5 (52.7-56.3) 24.0 (22.8-25.2) 7.8 (7.1-8.5) 4.3 (3.8-4.8) 10.0 (9.2-10.8)
Race/ethnicity
White 21.0 (20.2-21.9) 9.2 (8.7-9.8) 3.0 (2.7-3.4) 1.7 (1.5-2.0) 3.8 (3.4-4.1)
Black 21.8 (19.7-23.9) 7.0 (5.9-8.3) 3.4 (2.6-4.3) 2.0 (1.4-2.8) 6.1 (5.0-7.3)
Hispanic 15.8 (15.1-16.6) 6.0 (5.6-6.5) 2.4 (2.1-2.7) 1.4 (1.2-1.7) 3.4 (3.1-3.8)
Asian 19.4 (18.1-20.7) 9.0 (8.2-9.9) 3.2 (2.7-3.8) 1.6 (1.3-2.1) 2.4 (2.0-2.9)
Incidence rate ratio
White Reference Reference Reference Reference Reference
Black 1.04 (0.93-1.16) 0.76 (0.63-0.91) 1.11 (0.85-1.44) 1.18 (0.83-1.66) 1.61 (1.31-1.97)
Hispanic 0.75 (0.70-0.81) 0.65 (0.54-0.79) 0.78 (0.60-1.02) 0.83 (0.58-1.17) 0.91 (0.74-1.12)
Asian 0.92 (0.84-1.01) 0.98 (0.87-1.10) 1.05 (0.86-1.28) 0.95 (0.73-1.25) 0.64 (0.52-0.79)
AJCC Stage at diagnosis
I 4.9 (4.6-5.1) 2.5 (2.3-2.6) 0.6 (0.5-0.7) 0.3 (0.3-0.4) 0.7 (0.6-0.8)
II 8.2 (7.9-8.5) 3.3 (3.0-3.5) 1.2 (1.1-1.4) 0.7 (0.6-0.8) 1.8 (1.7-2.0)
III 3.7 (3.5-3.9) 1.5 (1.3-1.6) 0.7 (0.6-0.8) 0.4 (0.3-0.5) 0.7 (0.6-0.8)
IV 1.1 (1.0-1.2) 0.4 (0.4-0.5) 0.2 (0.1-0.2) 0.1 (0.1-0.2) 0.2 (0.2-0.3)
Grade
Low 7.5 (7.2-7.8) 4.7 (4.4-4.9) 1.1 (1.0-1.3) 0.3 (0.3-0.4) 0.3 (0.3-0.4)
High 10.2 (9.8-10.6) 2.9 (2.7-3.1) 1.6 (1.4-1.7) 1.2 (1.1-1.3) 3.2 (3.0-3.4)
Tumor size
≤2 cm 7.3 (7.0-7.7) 3.6 (3.4-3.8) 1.1 (1.0-1.2) 0.5 (0.4-0.6) 1.1 (1-1.2)
> 2 cm 10.4 (10.0-10.8) 4.0 (3.8-4.2) 1.6 (1.5-1.8) 0.9 (0.8-1.1) 2.4 (2.2-2.5)
Microinvasion 0.2 (0.1-0.2) c c c c
Diffuse 0.1 (0.1-0.2) c c c c
Lymph node involvement
No 9.3 (9.0 - 9.7) 3.9 (3.7-4.2) 1.2 (1.1-1.3) 0.6 (0.5-0.7) 1.9 (1.8-2.1)
Positive 9.1 (8.8 - 9.5) 3.8 (3.6-4.0) 1.6 (1.4-1.7) 1.0 (0.9-1.1) 1.7 (1.5-1.8)
Prior cancer
First primary 17.7 (17.2 - 18.2) 7.4 (7.1-7.7) 2.7 (2.5-2.9) 1.5 (1.4-1.7) 3.3 (3.1-3.6)
Non-first primary 1.9 (1.7 - 2.1) 0.7 (0.6-0.8) 0.3 (0.2-0.3) 0.2 (0.1-0.2) 0.4 (0.3-0.5)
Total 18.9 (18.4 - 19.4) 7.8 (7.5-8.2) 2.8 (2.6-3.0) 1.6 (1.5-1.8) 3.6 (3.4-3.8)
aHuman epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-).
b95% confidence interval. cStatistic not displayed because of fewer than 15 cases.
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women for ER-positive versus triple-negative breast can-
cers with regard to risk factor associations with reproduc-
tive history and oral contraceptive use [28], but not body
size or physical activity [27]. Future studies should con-
tinue to include information on HER2 status and also
address how risk factors are associated with breast cancer
subtypes, while considering age and race/ethnicity.
Genetic or other non-environmental contributions may
explain the higher incidence of triple-negative breast can-
cer among Black women than White women [30]. A
greater proportion of early breast cancer diagnoses are
associated with germline mutations of BRCA1/2 [38] and
TP53 [39]. BRCA1 mutations are associated with triple-
negative breast cancer [40], which may contribute to the
early age distribution of this subtype. Efforts to determine
the prevalence of BRCA1/2 mutations in White versus
Black populations, however, have been mixed [30,41]. Li
Fraumeni syndrome, due to TP53 mutations, also is
more prevalent in early-onset HR-/HER2+ breast cancer
[42], but the incidence of this disease is not known to dif-
fer by race/ethnicity [39].
Compared with older women, AYAs in our study were
more likely to be diagnosed with stage III/IV and higher
grade breast cancer and less likely to have been diag-
nosed with a previous cancer. Our multivariable-adjusted
stage and grade results are consistent with results from
univariate analyses in smaller studies [3,43]. Given the
lack of screening mammography advisements for AYAs,
whose diagnoses tend to follow identification of a palp-
able mass [44], it is not surprising that these women
would present with later stage, higher grade disease.
Despite the expectation that AYAs are more likely to
have genetic syndromes that predispose them to cancer
[39,41], we found that older women were more likely to
have a prior cancer; presumably because older women
had more time to acquire cancer-causing mutations.
Our study is the first, to our knowledge, to use popu-
lation-based registry data for which ER, PR, and HER2
status are sufficiently complete to present breast cancer
incidence rates in AYAs for the four major molecular
subtypes by race/ethnicity. Another strength of our
study is the relatively low percentage (16%) of women
whose breast cancers were unclassified because of miss-
ing ER, PR, or HER2 receptor information compared
with prior analyses [7,8]. To maximize the availability of
HER2-receptor status, however, our study was restricted
to diagnoses between 2005 and 2009, limiting the num-
ber of AYAs included. Although the reliability of ER
and PR tests can be controversial [45], evidence suggests
that results from a centralized pathology laboratory
agree with registry reports for ER and PR status [46].
However, HER2 testing between community-based hos-
pitals and centralized reference laboratories has been
found to contain some disagreement [47]. Consensus-
based methods to improve laboratory assays will con-
tinue to increase the reliability of ER, PR, and HER2
tests [48,49]. As with other studies that consider breast
cancer subtype according to receptor status, we may be
limited in that subtypes determined by ER, PR, and
HER2 receptor status serve only as a proxy for full
genetic profiling. These ER, PR, and HER2 designations,
however, guide clinical treatment [50] and are becoming
increasingly useful in epidemiologic research
[4,10,21,29]. Our study is also subject to the potential
misclassification of race/ethnicity, although we have
detected excellent overall agreement with self-reported
race/ethnicity for Whites and Blacks, and intermediate
agreement for Hispanics and Asians [51,52].
Conclusions
Our study adds to the evidence that AYA women with
breast cancer have larger proportions of HR+/HER2+,
HR-/HER2+, and triple-negative subtypes as compared
with older women. Compared with White AYAs, Black
and Hispanic women had lower incidence rates of HR
+/HER2- cancer, whereas Black women had higher rates
and Asians had lower rates of triple-negative breast can-
cer. In addition, AYAs are more likely to be of Black,
Hispanic, or Asian than of White race/ethnicity and
diagnosed with stage III/IV and high-grade disease com-
pared with older women. The subtype distributions may
explain the poorer breast cancer survival previously
observed in AYAs. Additional research is needed to
understand more fully the racial/ethnic differences in
breast cancer subtypes among AYAs.
 
Figure 2 Proportion of breast cancer subtypes among
California women by age group, 2005-2009. Hormone receptor
(HR)-positive and human epidermal growth factor receptor 2 (HER2)
negative (blue), HR+/HER2+ (red), HR-/HER2+ (green), and triple-
negative (purple).
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Table 3 Odds ratiosa for breast cancer diagnosis (15 to 39 versus 40 to 49 and 50+ years of age), by subtypeb
Total HR+/HER2- HR+/HER2+ HR-/HER2+ Triple-negative
Characteristics 15-39/40-49 15-39/50+ 15-39/40-49 15-39/50+ 15-39/40-49 15-39/50+ 15-39/40-49 15-39/50+ 15-39/40-49 15-39/50+
OR (95% CI)c OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Race/ethnicity
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aAdjusted for year at diagnosis, and the other variables in the table. bHuman epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor














AYA: adolescent and young adult; CCR: California Cancer Registry; CI:
confidence interval; ER: estrogen receptor; HER2: human epidermal growth
factor receptor 2; HR: hormone receptor; IHC: immunohistochemistry; IRR:
incidence rate ratio; OR: odds ratio; PR: progesterone receptor.
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